Scarica l'app Stockscreener
1.21
11.03%
-0.15
Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie
Is Akebia Therapeutics Inc. a stock for growth or value investorsJuly 2025 Trends & Weekly Watchlist for Consistent Profits - mfd.ru
STATE STREET CORP's Strategic Acquisition of Akebia Therapeutics Inc Shares - GuruFocus
Akebia Therapeutics at Guggenheim Summit: Aiming for Dialysis Market Leadership - Investing.com Canada
AKBA: VAFSEO and pipeline progress drive growth, with major clinical catalysts expected in the next year - TradingView
Akebia Therapeutics Spotlights VAFSEO Dialysis Push, TIW Dosing Plan and Rare Kidney Pipeline at Summit - Yahoo Finance
How sensitive is Akebia Therapeutics Inc. to inflation2025 Technical Patterns & Weekly Top Gainers Alerts - mfd.ru
Is Akebia Therapeutics Inc. (AX9) stock a top dividend aristocrat candidateTrend Reversal & High Accuracy Investment Entry Signals - mfd.ru
What downside risks could hit Akebia Therapeutics Inc. (AX9) stockMarket Activity Report & Growth Focused Stock Pick Reports - mfd.ru
Loss Report: Can Akebia Therapeutics Inc weather a recessionAnalyst Downgrade & Entry Point Confirmation Alerts - baoquankhu1.vn
Winners Losers: Should I hold or sell Victorias Secret Co now2025 Breakouts & Breakdowns & High Conviction Buy Zone Picks - baoquankhu1.vn
Q2 EPS Forecast for Akebia Therapeutics Lowered by Analyst - MarketBeat
Why The Narrative Around Akebia Therapeutics (AKBA) Is Shifting After New Valuation Reset - Yahoo Finance
Breaking Down Akebia Therapeutics: 4 Analysts Share Their Views - Benzinga
Akebia Therapeutics (NASDAQ:AKBA) Price Target Lowered to $4.00 at Piper Sandler - MarketBeat
Piper Sandler Lowers Akebia Therapeutics (AKBA) Price Target to $4.00 | AKBA Stock News - GuruFocus
Akebia Therapeutics (NASDAQ:AKBA) Earns "Buy" Rating from HC Wainwright - MarketBeat
Analyst Reiterates Buy Rating on Akebia Therapeutics (AKBA) with $6 PT | AKBA Stock News - GuruFocus
Akebia Therapeutics (NASDAQ:AKBA) CAO Sells $68,838.36 in Stock - MarketBeat
Akebia Therapeutics to present at Guggenheim Biotech Summit - Traders Union
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Surprises Report: Is Akebia Therapeutics Inc stock showing strong momentum - baoquankhu1.vn
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Akebia Therapeutics reports inducement grants under Nasdaq listing rule - marketscreener.com
Trading Recap: Will IVCPW benefit from AI trendsWeekly Investment Recap & Accurate Entry/Exit Alerts - baoquankhu1.vn
Earnings Beat: Is Akebia Therapeutics Inc stock showing strong momentumWeekly Market Report & Weekly Return Optimization Alerts - baoquankhu1.vn
Akebia Therapeutics (AKBA): A Potential 272% Upside In The Healthcare Sector - DirectorsTalk Interviews
Akebia Therapeutics signs new headquarters lease and amends executive severance agreements - Investing.com Canada
Akebia Therapeutics announces corporate updates and 2026 pipeline outlook - MSN
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Aug Catalysts: Can Akebia Therapeutics Inc weather a recessionInflation Watch & Reliable Intraday Trade Alerts - baoquankhu1.vn
Income Plays: Whats the beta of Akebia Therapeutics Inc stockQuarterly Trade Summary & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Akebia Therapeutics, Inc. (AKBA) Stock Analysis: A 275% Potential Upside That Investors Can't Ignore - DirectorsTalk Interviews
Highs Report: Can Akebia Therapeutics Inc deliver alpha2025 Support & Resistance & AI Enhanced Execution Alerts - baoquankhu1.vn
In the wake of Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) latest US$48m market cap drop, institutional owners may be forced to take severe actions - simplywall.st
Exit Recap: Can Akebia Therapeutics Inc benefit from deglobalizationJuly 2025 Action & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Analyst Calls: What’s the beta of Akebia Therapeutics Inc. stock2025 Retail Activity & Daily Volume Surge Signals - baoquankhu1.vn
Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts (NASDAQ:AKBA) - Seeking Alpha
Akebia reports first patient dosed in rare kidney disease trial By Investing.com - Investing.com Nigeria
Akebia Therapeutics (NASDAQ:AKBA) Shares Cross Below Fifty Day Moving AverageHere's Why - MarketBeat
Akebia (AKBA) Updates on Vafseo and Rare Kidney Disease Pipeline - GuruFocus
Akebia Therapeutics (AKBA) Reports Growth in Vafseo Prescriptions - GuruFocus
Akebia Therapeutics Outlines 2026 Vafseo Strategy and Pipeline - TipRanks
Akebia reports first patient dosed in rare kidney disease trial - Investing.com
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook - The Manila Times
Drugmaker maps next steps in Vafseo use and rare kidney disease trials - Stock Titan
How Akebia Therapeutics Inc. stock performs in weak economyJuly 2025 Closing Moves & AI Powered Buy and Sell Recommendations - Улправда
Akebia Therapeutics, Inc. (AKBA) Stock Analysis: Unveiling a Potential 262% Upside for Healthcare Investors - DirectorsTalk Interviews
What insider trading reveals about Akebia Therapeutics Inc. stockModel Comparison & HOKA buying tips before checkout - Улправда
How supply chain issues affect Akebia Therapeutics Inc. stock2025 Analyst Calls & Weekly Top Performers Watchlists - Улправда
Q32 Bio Shares Soar After Offloading Phase 2 Complement Drug to Akebia - MSN
Is Akebia Therapeutics Inc. stock affected by interest rate hikesMarket Sentiment Summary & Stock Timing and Entry Methods - ulpravda.ru
How Akebia Therapeutics Inc. (AX9) stock trades pre earningsCPI Data & Trade Opportunity Analysis Reports - Улправда
Can Akebia Therapeutics Inc. stock outperform in 2025 bull market2025 Year in Review & Long-Term Safe Return Strategies - Улправда
Akebia announces first patient dosed in Phase 2 trial of praliciguat - Yahoo Finance
Akebia Therapeutics begins phase 2 trial for rare kidney disease drug - Investing.com Nigeria
1.19%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):